Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The MDUK Oxford Neuromuscular Centre Seminar Series welcomes Prof Patrick Chinnery, Professor of Neurology and Head of the Department of Clinical Neurosciences at the University of Cambridge, and clinical neurologist at Addenbrooke’s Hospital. Prof Chinnery will be giving the talk entitled 'The Origin of Mitochondrial Diseases', and the event will be hosted by Dr Victoria Nesbitt



This seminar is intended for the personnel and students at the University of Oxford and the Oxford University Hospitals Foundation Trust.

Online Seminar – please register in advance for this Zoom meeting.





Prof Patrick ChinneryPatrick Chinnery is Professor of Neurology and Head of the Department of Clinical Neurosciences at the University of Cambridge and clinical neurologist at Addenbrooke’s Hospital. A Wellcome Trust Principal Research Fellow, his research lab is based in the MRC Mitochondrial Biology Unit. He is known for his expertise in rare inherited diseases that affect the nervous system. His lab has been studying the genetic basis of mitochondrial disorders for over two decades, harnessing the power of whole genome sequencing and developing new treatments through experimental medicine and early phase trials. He jointly chairs the NIHR BioResource for Translational Research in Common and Rare diseases, and is Clinical Director of the Medical Research Council.  During the COVID-19 pandemic he established the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP) to independently prioritise candidate treatments for evaluation in the nationally funded clinical trials platforms from phase 1 to phase 3, and is National Core Study lead for Therapeutics.